MedTrace Logo

Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis

NCT04506463 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 397

Last updated 2024-08-29

Study results available
· View outcomes & findings →

Summary

This is a phase IIb, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of MM-II in subjects with symptomatic knee OA as compared to matching placebo.

Conditions

  • Osteoarthritis of Knee

Interventions

DRUG

MM-II dose I

Intra-articular injection

DRUG

MM-II dose II

Intra-articular injection

DRUG

MM-II dose III

Intra-articular injection

DRUG

Placebo

Intra-articular injection

DRUG

Placebo

Intra-articular injection

DRUG

Placebo

Intra-articular injection

Sponsors & Collaborators

  • Moebius Medical Ltd.

    collaborator INDUSTRY

  • Nordic Bioscience Clinical Development (NBCD)

    collaborator UNKNOWN

  • Sun Pharmaceutical Industries Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-22
Primary Completion
2022-05-04
Completion
2022-08-10
FDA Drug
Yes

Countries

  • United States
  • Denmark
  • Hong Kong

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04506463 on ClinicalTrials.gov